MET and lung cancer: These innovative constructs, typified by the anti-c-MET-CARs, comprise an scFv derived from an anti-c-MET antibody, CD28, and CD3ζ (responsible for signaling), with a persistent aim to inhibit c-MET in lung cancer cells.